Overview of drugs approved by the FDA in 2022

QR Code

Overview of drugs approved by the FDA in 2022

The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were utilized. The search was conducted for the publicat...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, Yu. V. Gorbunova, Yu. A. Kolosov, M. A. Dzhavakhyan, I. E. Makarenko, R. V. Drai, A. V. Zaborovsky, O. V. Shatalova, A. V. Strygin, V. I. Petrov, A. P. Pleten, A. A. Prokopov, T. Yu. Tatarenko-Kozmina
Format:	Article
Language:	Russian
Published:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2023-11-01
Series:	Фармация и фармакология (Пятигорск)
Subjects:	fda biopharmaceuticals monoclonal antibodies drug design trends
Online Access:	https://www.pharmpharm.ru/jour/article/view/1353
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Original drugs approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2024
by: D. V. Kurkin, et al.
Published: (2025-07-01)

Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease
by: Israa J. Hakeem, et al.
Published: (2025-05-01)

Activity of soil fluorescein diacetate (FDA) hydrolase under long-term fertilization
by: MA Xing-zhu
Published: (2010-07-01)

A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational Study
by: Ajay Kumar Shukla, et al.
Published: (2025-01-01)

Strategic aspects of staffing industrial biopharmaceutical companies
by: A. S. Glazkova, et al.
Published: (2020-01-01)

The investigation of kinetics dissolution of prolonged indapamide drugs in biorelevant media
by: E. Yu. Sannikova, et al.
Published: (2013-03-01)

In Silico Study of FDA-Approved Drugs on <i>Leishmania infantum</i> CYP51, a Drug Repositioning Approach in Visceral Leishmaniasis
by: Juan Diego Guarimata, et al.
Published: (2024-11-01)

Analyzing FDA's approaches to using electronic health record and medical claims data to support regulatory decision making
by: Ksenia S. Radaeva, et al.
Published: (2023-10-01)

In Silico Investigation of TATA-Binding Protein as a Therapeutic Target for Chagas Disease: Insights into FDA Drug Repositioning
by: Carlos Gaona-López, et al.
Published: (2025-06-01)

QUERCETIN PHYSICAL-CHEMICAL CHARACTERISTICS’ DEFINITION
by: I. V. Kovalevska
Published: (2014-04-01)

RETRACTED: The biopharmaceutical classiﬁcation of medicinal substances
by: G. V. Ramenskaya, et al.
Published: (2011-03-01)

PROBLEMS OF CONFORMITY OF THE RECORDS INTEGRITY WITH THE REQUIREMENTS OF GOOD MANUFACTURING PRACTICE. REPORT 1. ACTUALITY OF THE RECORDS INTEGRITY CONSERVATION
by: I. A. Osmolovskaya, et al.
Published: (2019-01-01)

SAFETY OF BIOLOGICAL PREPARATIONS AND SMALL MOLECULES. ARE THERE ANY DIFFERENCES?
by: A. S. Kolbin, et al.
Published: (2013-05-01)

DISINTEGRANTS AND THEIR INFLUENCE ON THE DISSOLUTION OF SUBSTANCES OF BIOPHARMACEUTICAL CLASSIFICATION SYSTEM CLASSES
by: I. E. Smekhova, et al.
Published: (2019-01-01)

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents
by: Ute Hennrich, et al.
Published: (2025-06-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
by: Akimasa Sanagawa, et al.
Published: (2018-06-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

RECOMBINANT HUMAN LUTEINIZING HORMONE FOR THE TREATMENT OF INFERTILITY: THE GENERATION OF PRODUCER CELL LINES
by: N. A. Orlova, et al.
Published: (2017-12-01)

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-06-01)

Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan
by: V. A. Maliyevskiy, et al.
Published: (2016-02-01)

Methodological and regulatory aspects of pharmaceutical development of biological products
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
by: D. V. Kurkin, et al.
Published: (2023-05-01)

Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained Release
by: E. V. Flisyuk, et al.
Published: (2021-12-01)

Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance
by: Mingming Yang, et al.
Published: (2025-06-01)

CREATION AND PHARMACOTECHNOLOGICAL INVESTIGATIONS OF INNOVATIVE DOSAGE FORMS OF MEXIDOL
by: E. F. Stepanova, et al.
Published: (2019-01-01)

Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis
by: Y. M. Spivakovskiy, et al.
Published: (2016-02-01)

Vaccine Dosing Considerations in Product Labels and ACIP Recommendations: A Review
by: Kunal Saxena, et al.
Published: (2025-06-01)

“Common questions and misconceptions about dietary supplements and the industry - What does science and the law really say?“
by: Jose Antonio, et al.
Published: (2025-12-01)

ANALYSIS OF INTERNATIONAL REQUIREMENTS FOR DESIGNING OF CLINICAL TRIALS
by: O. S. Kobyakova, et al.
Published: (2019-01-01)

Advances in the Study of Protein Deamidation: Unveiling Its Influence on Aging, Disease Progression, Forensics and Therapeutic Efficacy
by: Sunil S. Adav
Published: (2025-06-01)

Influence of Substrate Concentrations on the Performance of Fed-Batch and Perfusion Bioreactors: Insights from Mathematical Modelling
by: John J. Fitzpatrick, et al.
Published: (2025-05-01)

Biowaiver as a Bioequivalence Study Option
by: E. A. Volkova, et al.
Published: (2024-02-01)

Economic barriers restraining the production of therapeutic recombinant human trypsin. Use of innovative technologies to overcome them
by: S. V. Ponomarenko
Published: (2018-11-01)

Transceiver Design for an FDA-MIMO Radar and MIMO Communication Spectral Coexistence System
by: Qihang XU, et al.
Published: (2025-08-01)

Valid cardiac biomarkers. Part I
by: V. A. Metelskaya, et al.
Published: (2020-09-01)

Analysis of RWD/RWE recommendations and guidelines for 2021. International experience on the example of USA
by: A. Kurylev
Published: (2022-11-01)

BIOPHARMACEUTICAL PROPERTIES OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
by: Y. I. Kulinich
Published: (2012-03-01)